|
厄妥索单抗
厄妥索单抗（INN：Ertumaxomab），或译厄马索单抗，商品名Rexomun，是一种三功能单克隆抗体，设计用于治疗乳癌和腹膜癌病。[1][2]它通过将T淋巴细胞和巨噬细胞与癌细胞连接起来发挥作用。[3]
由于费森尤斯开发计划的改变，评估乳癌治疗的II期临床试验被终止。[4]（以便他们可以专注于其他产品如卡妥索单抗（商品名Removab）。[5]:35）
参考资料
|
|---|
| | 血管生成素 | |
|---|
| | CNTF | |
|---|
| | EGF（ErbB）
| |
|---|
| | FGF | | FGFR1 | |
|---|
| | FGFR2 |
- 受體激動劑：Ersofermin
- FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22)
- Palifermin
- Repifermin
- Sprifermin
- Trafermin
|
|---|
| | FGFR3 | |
|---|
| | FGFR4 | |
|---|
| | Unsorted | |
|---|
|
|---|
| | HGF (c-Met) | |
|---|
| | IGF | |
|---|
| | LNGF (p75NTR) | |
|---|
| | PDGF | |
|---|
| | RET (GFL) | |
|---|
| | SCF (c-Kit) | |
|---|
| | TGFβ | |
|---|
| | Trk | | TrkA |
- Negative allosteric modulators: VM-902A
|
|---|
| | TrkB |
- 受體激動劑：3,7-DHF
- 3,7,8,2'-THF
- 4'-DMA-7,8-DHF
- 7,3'-DHF
- 7,8-DHF
- 7,8,2'-THF
- 7,8,3'-THF
- 阿米替林
- BDNF
- BNN-20
- Deoxygedunin
- Deprenyl
- Diosmetin
- DMAQ-B1
- HIOC
- LM22A-4
- N-乙酰血清素
- NT-3
- NT-4
- Norwogonin (5,7,8-THF)
- R7
- TDP6
|
|---|
| | TrkC | |
|---|
|
|---|
| | VEGF | |
|---|
| | 其他 |
- Additional growth factors: Adrenomedullin
- Colony-stimulating factors (see here instead)
- Connective tissue growth factor (CTGF)
- Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)
- 紅血球生成素 (see here instead)
- 葡萄糖-6-磷酸異構酶（GPI; PGI, PHI, AMF）
- Glia maturation factor (GMF)
- Hepatoma-derived growth factor (HDGF)
- 白细胞介素/T-cell growth factors (see here instead)
- 白血病抑制因子（LIF）
- Macrophage-stimulating protein (MSP; HLP, HGFLP)
- Midkine (NEGF2)
- Migration-stimulating factor (MSF; PRG4)
- Oncomodulin
- Pituitary adenylate cyclase-activating peptide (PACAP)
- Pleiotrophin
- Renalase
- 促血小板生成素 (see here instead)
- Wnt信号通路
- Additional growth factor receptor modulators: Cerebrolysin (neurotrophin mixture)
|
|---|
| |
|
|
|
